{"id":399852,"date":"2020-12-15T08:23:07","date_gmt":"2020-12-15T13:23:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399852"},"modified":"2020-12-15T08:23:07","modified_gmt":"2020-12-15T13:23:07","slug":"oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/","title":{"rendered":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Dec. 15, 2020<\/span> \/PRNewswire\/ &#8212; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmstr\u00f6m has been appointed Director of Investor Relations. Linda has more than 15 years of experience from the life science industry. Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations. Rein Piir who has been responsible for the Investor Relations function during the last four years will continue to work as a senior advisor.<\/p>\n<p>\n        <b>For more information, please contact:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Rolf Gulliksen<\/span>, Global Head of Corporate Communications<br \/>E-mail: <a target=\"_blank\" href=\"mailto:rolf.gulliksen@oncopeptides.com\" rel=\"nofollow noopener noreferrer\">rolf.gulliksen@oncopeptides.com<\/a><br \/>Mobile: +46 70\u00a0262 96 28<\/p>\n<p>The information in this press release was submitted for publication on <span class=\"xn-chron\">December 15, 2020<\/span> at 14:00 (CET).<\/p>\n<p>\n        <b>About melflufen<\/b>\n      <\/p>\n<p>Melflufen (INN melphalan flufenamide)\u00a0is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden.\u00a0In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.\u00a0In the pivotal phase 2 HORIZON study melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable safety profile in heavily pretreated patients with relapsed refractory multiple myeloma, with primarily hematologic Adverse Events (AE) and a low incidence of non-hematologic AEs. \u00a0<\/p>\n<p>\n        <b>About Oncopeptides <\/b>\n      <\/p>\n<p>Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study.\u00a0Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma.\u00a0The FDA,\u00a0has\u00a0granted the\u00a0New Drug Application a priority review, with a PDUFA date of <span class=\"xn-chron\">February 28<\/span>, 2021.Oncopeptides&#8217; global Headquarters is in <span class=\"xn-location\">Stockholm, Sweden<\/span> and the U.S. Headquarters is situated in <span class=\"xn-location\">Boston, Mass.<\/span> The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013500-1&amp;h=844893829&amp;u=http%3A%2F%2Fwww.oncopeptides.com%2F&amp;a=www.oncopeptides.com\" rel=\"nofollow noopener noreferrer\">www.oncopeptides.com<\/a>.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013500-1&amp;h=1493160133&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013500-1&amp;h=3675895523&amp;u=https%3A%2F%2Fnews.cision.com%2Foncopeptides-ab%2Fr%2Foncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-rela%2Cc3255222&amp;a=https%3A%2F%2Fnews.cision.com%2Foncopeptides-ab%2Fr%2Foncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-rela%2Cc3255222\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/oncopeptides-ab\/r\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-rela,c3255222<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3013500-1&amp;h=2616979626&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3255222%2F1348831.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3255222%2F1348831.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/15404\/3255222\/1348831.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Press release &#8211; Oncopeptides strengthens its organization with Director of Investor Relations<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations-301192952.html\">http:\/\/www.prnewswire.com\/news-releases\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations-301192952.html<\/a><\/p>\n<p>SOURCE  Oncopeptides AB<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO24514&amp;Transmission_Id=202012150819PR_NEWS_USPR_____IO24514&amp;DateId=20201215\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire STOCKHOLM, Dec. 15, 2020 \/PRNewswire\/ &#8212; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmstr\u00f6m has been appointed Director of Investor Relations. Linda has more than 15 years of experience from the life science industry. Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations. Rein Piir who has been responsible for the Investor Relations function during the last four years will continue to work as a senior advisor. For more information, please contact: Rolf Gulliksen, Global Head of Corporate CommunicationsE-mail: rolf.gulliksen@oncopeptides.comMobile: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399852","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Dec. 15, 2020 \/PRNewswire\/ &#8212; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmstr\u00f6m has been appointed Director of Investor Relations. Linda has more than 15 years of experience from the life science industry. Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations. Rein Piir who has been responsible for the Investor Relations function during the last four years will continue to work as a senior advisor. For more information, please contact: Rolf Gulliksen, Global Head of Corporate CommunicationsE-mail: rolf.gulliksen@oncopeptides.comMobile: &hellip; Continue reading &quot;Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T13:23:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations\",\"datePublished\":\"2020-12-15T13:23:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/\"},\"wordCount\":546,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO24514&amp;sd=2020-12-15\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/\",\"name\":\"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO24514&amp;sd=2020-12-15\",\"datePublished\":\"2020-12-15T13:23:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO24514&amp;sd=2020-12-15\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO24514&amp;sd=2020-12-15\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/","og_locale":"en_US","og_type":"article","og_title":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Dec. 15, 2020 \/PRNewswire\/ &#8212; Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmstr\u00f6m has been appointed Director of Investor Relations. Linda has more than 15 years of experience from the life science industry. Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations. Rein Piir who has been responsible for the Investor Relations function during the last four years will continue to work as a senior advisor. For more information, please contact: Rolf Gulliksen, Global Head of Corporate CommunicationsE-mail: rolf.gulliksen@oncopeptides.comMobile: &hellip; Continue reading \"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T13:23:07+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations","datePublished":"2020-12-15T13:23:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/"},"wordCount":546,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/","name":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15","datePublished":"2020-12-15T13:23:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO24514&amp;sd=2020-12-15"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-strengthens-its-organization-by-appointing-linda-holmstrom-as-director-of-investor-relations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncopeptides strengthens its organization by appointing Linda Holmstr\u00f6m as Director of Investor Relations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399852"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399852\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}